NPCE
NeuroPace, Inc.
$15.04
-0.63
(-4.02%)
Mkt Cap
532.00M
Volume
32,229
52W Range
7.563-19.6
Sector
Healthcare
Beta
1.93
EPS (TTM)
-0.66
P/E Ratio
-23.54
Revenue (TTM)
99.99M
Rev Growth (5Y)
+19.4%
EPS Growth (5Y)
N/A
Company Description
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 99.99M | 79.91M | 65.42M | 45.52M | 45.18M | 41.14M | 36.97M |
| Net Income | (21.46M) | (27.14M) | (32.96M) | (47.08M) | (36.08M) | (24.28M) | (29.97M) |
| EPS | -0.66 | -0.93 | -1.27 | -1.91 | -2.17 | -2.17 | -2.70 |
| Free Cash Flow | (11.34M) | (18.25M) | (19.87M) | (37.47M) | (24.96M) | (21.67M) | (25.49M) |
| FCF / Share | -0.35 | -0.63 | -0.77 | -1.52 | -1.50 | -1.95 | -2.30 |
| Operating CF | (11.01M) | (17.95M) | (19.70M) | (36.87M) | (24.58M) | (21.61M) | (25.03M) |
| Total Assets | 105.56M | 94.65M | 107.65M | 114.11M | 133.56M | 55.95M | 21.09M |
| Total Debt | 70.84M | 73.34M | 72.39M | 69.77M | 49.85M | 52.86M | 62.80M |
| Cash & Equiv | 21.69M | 13.43M | 18.06M | 6.61M | 19.19M | 26.39M | 4.12M |
| Book Value | 19.03M | 8.01M | 20.65M | 34.78M | 73.50M | (147.83M) | (129.35M) |
| Return on Equity | -1.13 | -3.39 | -1.60 | -1.35 | -0.49 | N/A | N/A |
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.59M | 27.35M | 23.52M | 22.52M | 21.47M | 21.06M | 19.26M | 18.12M | 18.01M | 16.43M | 16.51M | 14.47M |
| Net Income | (2.73M) | (3.50M) | (8.65M) | (6.59M) | (5.25M) | (5.45M) | (7.51M) | (8.93M) | (6.20M) | (7.26M) | (9.12M) | (10.38M) |
| EPS | -0.08 | -0.11 | -0.26 | -0.21 | -0.18 | -0.19 | -0.26 | -0.32 | -0.24 | -0.28 | -0.36 | -0.41 |
| Free Cash Flow | 409,000 | (1.97M) | (2.25M) | (7.52M) | (4.84M) | (1.82M) | (3.96M) | (7.63M) | (3.37M) | (2.31M) | (4.36M) | (9.83M) |
| FCF / Share | 0.01 | -0.06 | -0.07 | -0.24 | -0.16 | -0.06 | -0.14 | -0.27 | -0.13 | -0.09 | -0.17 | -0.39 |
| Operating CF | 506,000 | (1.94M) | (2.09M) | (7.48M) | (4.80M) | (1.72M) | (3.90M) | (7.53M) | (3.34M) | (2.30M) | (4.36M) | (9.70M) |
| Total Assets | 105.56M | 107.25M | 106.11M | 110.20M | 94.65M | 96.30M | 94.39M | 98.85M | 107.65M | 99.30M | 102.23M | 106.27M |
| Total Debt | 70.84M | 71.18M | 71.52M | 73.15M | 73.34M | 73.50M | 73.66M | 73.08M | 72.39M | 71.69M | 71.02M | 70.37M |
| Cash & Equiv | 21.69M | 20.65M | 22.86M | 27.02M | 13.43M | 15.42M | 12.84M | 13.00M | 18.06M | 9.72M | 7.86M | 6.72M |
| Book Value | 19.03M | 18.52M | 19.44M | 24.27M | 8.01M | 9.82M | 9.88M | 14.34M | 20.65M | 16.36M | 21.23M | 27.49M |
| Return on Equity | -0.14 | -0.19 | -0.45 | -0.27 | -0.66 | -0.56 | -0.76 | -0.62 | -0.30 | -0.44 | -0.43 | -0.38 |
NPCE News
NeuroPace (NPCE) Moves 6.3% Higher: Will This Strength Last?
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
NeuroPace (NASDAQ:NPCE) & Advanced Biomedical Technologies (OTCMKTS:ABMT) Head to Head Survey
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
Contrasting NeuroPace (NASDAQ:NPCE) & Integer (NYSE:ITGR)
NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue?
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High?
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Brokerages
NPCE RNS System Explained: Growth Drivers and Setup for 2026